These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24834904)

  • 1. Programming implantable cardioverter-defibrillators in primary prevention: higher or later.
    Clementy N; Pierre B; Simeon E; Lallemand B; Fauchier L; Babuty D
    Arch Cardiovasc Dis; 2014 May; 107(5):308-18. PubMed ID: 24834904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causes and Prevention of Inappropriate Implantable Cardioverter-Defibrillator Shocks.
    Kulkarni N; Link MS
    Card Electrophysiol Clin; 2018 Mar; 10(1):67-74. PubMed ID: 29428143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A life-threatening arrhythmia induced by inappropriate activation of an implantable cardioverter defibrillator.
    Kadmon E; Kusniec J; Strasberg B
    Europace; 2009 Dec; 11(12):1716-8. PubMed ID: 19762330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverter-defibrillator therapy and mortality in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial.
    Ruwald MH; Zareba W; Jons C; Zhang C; Ruwald AC; Olshansky B; McNitt S; Bloch Thomsen PE; Shoda M; Merkely B; Moss AJ; Kutyifa V
    Circulation; 2013 Aug; 128(7):694-701. PubMed ID: 23881862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study.
    Friedman PA; McClelland RL; Bamlet WR; Acosta H; Kessler D; Munger TM; Kavesh NG; Wood M; Daoud E; Massumi A; Schuger C; Shorofsky S; Wilkoff B; Glikson M
    Circulation; 2006 Jun; 113(25):2871-9. PubMed ID: 16769912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pacing-dependency following implantable cardioverter-defibrillator shocks: a case report.
    Webber MR; Levings SL; Stiles MK
    J Electrocardiol; 2013; 46(2):142-4. PubMed ID: 23177276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the benefits of implantable cardioverter-defibrillator therapy: "is less more"?
    Jackson LR; Daubert JP; Thomas KL
    Prog Cardiovasc Dis; 2012; 54(4):372-8. PubMed ID: 22226007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the programming of implantable cardioverter-defibrillators in New Zealand.
    Webber MR; Stiles MK
    Heart Lung Circ; 2012 Dec; 21(12):765-77. PubMed ID: 22926144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple shocks after upgrade of an implantable cardioverter-defibrillator to a cardiac resynchronization therapy-defibrillator device.
    Francisco GM; Sharma S; Dougherty AH; Kantharia BK
    Cardiol J; 2009; 16(5):473-6. PubMed ID: 19753529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inappropriate shock despite successful termination of supraventricular tachycardia by antitachycardia pacing during charging.
    Bernier M; Essebag V
    Pacing Clin Electrophysiol; 2010 Sep; 33(9):e81-3. PubMed ID: 20230474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
    Daubert JP; Zareba W; Cannom DS; McNitt S; Rosero SZ; Wang P; Schuger C; Steinberg JS; Higgins SL; Wilber DJ; Klein H; Andrews ML; Hall WJ; Moss AJ;
    J Am Coll Cardiol; 2008 Apr; 51(14):1357-65. PubMed ID: 18387436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal programming of implantable cardiac-defibrillators.
    Madhavan M; Friedman PA
    Circulation; 2013 Aug; 128(6):659-72. PubMed ID: 23918187
    [No Abstract]   [Full Text] [Related]  

  • 15. Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks.
    Silver MT; Sterns LD; Piccini JP; Joung B; Ching CK; Pickett RA; Rabinovich R; Liu S; Peterson BJ; Lexcen DR;
    Heart Rhythm; 2015 Mar; 12(3):545-553. PubMed ID: 25460168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent inappropriate shocks from an implantable cardioverter defibrillator:
    Moore DR; Kok LC; Vijayaraman P
    J Cardiovasc Electrophysiol; 2004 Jan; 15(1):116-7. PubMed ID: 15028086
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of ventricular tachycardia degeneration by low-energy implantable cardioverter-defibrillator shocks: a case report.
    Cagli KE; Guray U; Akpinar I; Sen N; Aras D; Topaloglu S
    J Electrocardiol; 2010; 43(1):68-70. PubMed ID: 19446839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
    Wilkoff BL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shock avoidance and the newer tachycardia therapy algorithms.
    Rajamani K; Goldberg AS; Wilkoff BL
    Cardiol Clin; 2014 May; 32(2):191-200. PubMed ID: 24793796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.